. *the lit. shows that there isn’t an association. In fact, in $MRK failed BACE inhibitor trial, ↓ αβ load generated worse clinical outcomes. Meanwhile, $LLY solanezumab continues trudge on in Ph3 OLE, eating away precious govt funds after having failed 3x prev in AD $BIIB